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Clostridium perfringens is a normal bacterial flora of the small and large intestines of humans and other animals. The current study
investigates the potential use of a noncytotoxic C. perfringens as an oral vaccine vehicle for expression and intestinal delivery of a large
amount of SIV antigens. Here we report the construction of a recombinant C. perfringens vaccine vector expressing high levels of SIV p27
during sporulation. Following oral administration of this recombinant C. perfringens vaccine vector to mice, large amounts of intact p27
protein were detected in the terminal ileum where the majority of Peyer’s Patches (PPs) are located. Furthermore, dendritic cells (DCs)
beneath the mucosal surface in the PPs were able to capture SIV p27 antigen, when PPs were exposed to C. perfringens expressing SIV p27
antigen. In addition, uptake of C. perfringens was able to induce maturation of mouse DCs. These results support the potential use of C.
perfringens as an oral SIV/HIV vaccine vector.
D 2004 Elsevier Inc. All rights reserved.
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Heterosexual transmission accounts for most of the
worldwide spread of HIV infection. An effective vaccine
against HIV/SIV must induce mucosal immunity to prevent
systemic infection from the mucosal surface of the genital
organs. A number of efforts have been made to develop a
vaccine that elicits a mucosal immune response against SIV.
Induction of SIV-specific IgA and cytotoxic T lymphocytes
(CTL) in vaginal and rectal mucosal surfaces have been
demonstrated with particulate antigens (Klavinskis et al.,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.08.018
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E-mail address: pgupta1@pitt.edu (P. Gupta).2000), microencapsulated killed virus (Israel et al., 1999;
Lerner et al., 1996), and immunization with DNA vaccine or
live attenuated viral vectors encoding viral antigens or
noninfectious virions (Baig et al., 2002; Stevceva et al.,
2002; Wang et al., 2000). In most mucosal vaccine trials,
immunogens in the form of a DNA vaccine or live
attenuated virus are administered directly into mucosal
sites, i.e., vaginal, rectal, or intranasal (Belyakov et al.,
1998; Klavinskis et al., 1999, 2000). However, such an
immunization procedure is unlikely to be employed for
large-scale vaccination of human.
Because the gut is the major site of CD4+ T cell depletion
and SIV replication (Kraehenbuhl, 1998; Stahl-Hennig et
al., 1999; Veazey et al., 1999), and the mucosal layer of the
gastrointestinal (GI) tract is naturally exposed to bacteria in
the lumen, a bacterial vector provides an attractive vehicle04) 226–233
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lymphoid tissues (GALT) to stimulate mucosal immunity.
Bacterial vectors for oral delivery of antigens have several
advantages including a large multivalent antigen capacity,
an adjuvant property by presenting immune stimulatory
bacterial molecules and development of specific protective
mucosal immune response. Immunization of the intestinal
mucosal surface should also sensitize other mucosal
surfaces at remote sites, namely genital surfaces, and induce
both mucosal and systemic immune responses (Ogra et al.,
1999). In this study, a commensal bacterium, Clostridium
perfringens, has been investigated for the possible usage as
a mucosal vaccine vector for expression and delivery of SIV
antigens to the gut. C. perfringens, a gram-positive,
anaerobic bacterium, is a normal flora bacterium of the
small and large intestines of humans and other animals. A
small percentage (b5%) of C. perfringens isolates produce
an enterotoxin (CPE) that causes a mild food poisoning and
some mild nonfood-borne GI diseases. When foods con-
taminated with cpe-positive vegetative C. perfringens are
ingested, conditions in the upper GI tract induce C.
perfringens sporulation. During this in vivo sporulation,
there is expression of CPE protein in the ileum that causes
diarrhea (McClane, 1998; Rood and Cole, 1991).
In this report, we describe construction of a recombinant
C. perfringens expressing high levels of the SIV p27 protein
from the cpe promotor. We also evaluated the effectiveness
of mucosal delivery of SIV antigen by the recombinant C.
perfringens strain.Fig. 1. Western blot analysis of SIV p27 expression in transformed C.
perfringens. Lanes 1–3, SIV p55 as the quantitative standards; lane 4,
buffer control; lane 5, Cp/p27 Spores: C. perfringens transformed by cp27
in sporulating culture; lane 6, Cp/p27 Veg.: C. perfringens transformed by
cp27 in vegetative culture; lane 7, Cp/pJRC200 Spores: C. perfringens
transformed by control vector in sporulating culture; lane 8, Cp/pJRC200
Veg.: C. perfringens transformed by control vector in vegetative culture.Results
Construction of a recombinant C. perfringens vaccine strain
carrying SIV p27 gene
To investigate the feasibility of C. perfringens used as a
vaccine vector, a recombinant C. perfringens strain express-
ing the SIV protein p27 from SIV 17e-Fr was constructed,
because the SIV gag p27 protein contains epitopes for both
cellular and humoral immune responses (Valentine et al.,
1996). SIV 17e-Fr was chosen as the source of p27, because
SIV17e-Fr has been shown to elicit immune responses
capable of conferring protection against challenge SIV in
immunized monkeys (Fuller et al., 1997; Murphey-Corb et
al., 1999). For construction of the recombinant vaccine
strain, we used a C. perfringens/E. coli shuttle plasmid
pJRC200, which contains the wild-type cpe gene. The
pJRC200 was digested with restriction enzymes to remove
the cpe cytotoxicity region, leaving the cpe promoter and a
small amount of 5Vand 3Vsequences for transcription/trans-
lation efficiency and mRNA stabilization, respectively. The
digested plasmid was then ligated with the p27 ORF
amplified from SIV 17e-Fr, and the resulting plasmid,
named cp27, was then introduced by electroporation into
cpe-negative C. perfringens isolate ATCC3624. This trans-formant expressed an estimated 32-kDa CPE–p27 fusion
protein under the control of the CPE promoter.
Expression of the CPE–SIV p27 fusion protein by the
recombinant C. perfringens vaccine construct
Because the cpe promotor only functions during
sporulation, expression of the CPE–p27 fusion protein
was induced by growing the recombinant C. perfringens
vaccine strain in MDS to promote sporulation. Cell lysates
were prepared from the bacterial pellets following washing
and sonicating them in PBS, and subjected to a semi-
quantitative Western blot analysis using anti-SIV poly-
clonal antibody and purified SIV p55 as a quantitation
standard. Results shown in Fig. 1 indicate that an intact
32-kDa fusion protein was present in the sporulating cell
lysate of the cp27 vaccine strain. As judged from a
standard curve prepared with purified p55, it appears that
20–30 Ag of SIV p27 fusion protein was produced per
milliliter (1  108 to 2  108 cells) of sporulating culture
that amounts to 70 Ag of the fusion protein per milligram
of bacterial proteins. No fusion protein was detected in the
vegetative cell lysate of cp27 transformed clostridia
(compare lane 5 vs. lane 6, Fig. 1), which is consistent
with the notion that the expression of the 32-kDa fusion
protein was driven by the cpe promotor.
We also made a codon-optimized (i.e., optimized codon
usage based on C. perfringens preferred codon usage) SIV
p27 gene with the help of Dr. Andrea Gambotto of the
University of Pittsburgh using a patented technology (Gao
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p27 gene was expressed under the control of the cpe
promoter in C. perfringens, the level of expression of p27
was as high as that of the wild-type gene (data are not
shown).
To determine the localization of the fusion protein inside
sporulating cells of the recombinant C. perfringens
expressing SIV p27, bacterial cells were subjected to
immunogold electron microscopy with monoclonal anti-
SIV p27 antibody. Results in Fig. 2A show that p27 protein
was exclusively in the inclusion body in the cytoplasm of
the sporulating cells. No p27 protein was detected in
sporulating bacterium stained with isotype control antibody
(Fig. 2B).
Detection of intact SIV p27 fusion protein in terminal ileum
of mice following oral feeding
We next determined whether the fusion protein pro-
duced by the recombinant C. perfringens vaccine construct
could survive the harsh upper GI environment and be
delivered to the terminal ileum, where the majority of PPs
are located. Mice were orally fed with sporulating C.
perfringens recombinants. Ninety minutes (time needed for
movement of gastric content to lower part of small
intestine by the intestinal motility in mice) after that
feeding, the contents of the small intestines were extracted
and subjected to a Western blot analysis. Fig. 3A shows
high level of p27 detected in small intestinal content
following the feeding, and Fig. 3B shows the intensity of
the 32-kDa band from densitometry of Western blots
throughout the entire small intestine of three mice. These
results demonstrate that the highest levels of the 32-kDa
CPE–p27 fusion protein were present in the lower part of
ileum, where the majority of GALT is located. These data
indicate that the CPE–p27 fusion protein produced by the
recombinant C. perfringens can be delivered to theFig. 2. Immunogold-stained EM picture of SIV p27 antigen (arrows) in inclusion b
(A) and isotype control antibody (B).terminal ileum, where M cells in PPs can efficiently
transport antigens to antigen-presenting cells and stimulate
mucosal immune responses.
Uptake of C. perfringens expressing SIV p27 antigen by
cultured DCs and DCs in the PPs
To test whether SIV p27 produced by recombinant C.
perfringens could be uptaken by DCs, which are potent
antigen-presenting cells, immature bone-marrow-derived
DCs were pulsed for 2 h with the lysate prepared from
sporulating recombinant C. perfringens expressing p27.
Following incubation, DCs were stained with anti-CD11C
and anti-p27 antibodies for detection of DCs and p27,
respectively. Fig. 4A shows that the p27 fusion protein
expressed by the bacteria was taken-up very efficiently by
DCs. Similar results were obtained when DCs were
pulsed with intact bacteria expressing SIV p27. To
investigate whether DCs in intestinal PPs could take up
the p27 fusion protein present in the lumen, the lysate
prepared from sporulating C. perfringens cells expressing
the fusion protein was injected inside the lumen of the
ligated intestinal segment. After incubation for 3.5 h, the
PP in this segment was subjected to in situ immuno-
fluoresence staining for the detection of DCs and p27.
Fig. 4B shows the expression of SIV p27 protein inside
DCs in the PP. The results demonstrate that DCs in
intestinal PPs, like bone-marrow-derived DCs, can effi-
ciently take up the p27 fusion protein delivered into the
lumen, as necessary to stimulate an SIV-specific immune
response.
Maturation of DCs following uptake of C. perfringens
expressing SIV p27 antigen
CD40 and CD86 have been used as markers for
maturation of DCs (Morris et al., 2000; Muraille et al.,ody of an endospore containing C. perfringens using anti-SIV p27 antibody
Fig. 3. Detection of SIV p27 in small intestines of mice fed with C. perfringens expressing SIV p27. (A) The Western Blot analysis for p27 of small intestinal
content extract following the feeding of one mouse. (B) The intensity of the 32-kDa band from densitometry of Western blots throughout the entire small
intestine. Error bars, SEs for three mice.
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expressing CD40 and CD86 in bone-marrow-derived DCs
pulsed for 2 h with C. perfringens expressing SIV p27. The
results indicate that percentage of cells expressing CD86
and CD40 in DCs co-cultured with C. perfringens express-
ing SIV p27 were very similar to those observed in control
LPS-treated DCs and higher than control DCs cultured in
medium alone. Furthermore, the mean fluorescence inten-
sity (MFI) of the CD86- and CD40-positive DCs treated
with the C. perfringens was significantly higher than p27
protein-treated DCs and control DCs and even higher than
DCs stimulated by LPS (Figs. 5C, D). MHC class II is also
known to be up-regulated upon DC maturation. MFI of
MHC class II was also increased over the control DCs alone
and p27 protein treated DCs, and was similar to that of LPS-
treated DCs (data not shown). These results demonstrate
that C. perfringens is able to induce maturation of DCs.Fig. 4. Uptake of C. perfringens expressing p27 by DCs. (A) SIV p27 (green) exp
CD11c+ DC (red) following co-incubation in vitro. (B) Detection of SIV p27 inside
The arrow shows p27 antigen (green) inside DC (red), which is shown in detailDiscussion
Administration of antigens to mucosal surfaces is
probably the best method for inducing mucosal immune
responses at local as well as distant sites. The oral route of
immunization, because of practical advantages and its
capacity to stimulate both mucosal and systemic immunity,
could be used for prophylactic and therapeutic vaccination
against HIV. However, to get a high level of mucosal
immune response, a vaccine has to deliver a relatively large
amount of antigens to the inductive sites of the mucosal
immune system, represented by PPs in GALT, which are
mainly in terminal ileum in human (Didierlaurent et al.,
2002; Ogra et al., 1999).
In this study, we showed that a recombinant C.
perfringens vaccine construct produced a high level of
SIV p27 protein in vitro under sporulating conditions. Toressed by recombinant C. perfringens was uptaken by bone-marrow derived
CD11c+ DCs in Peyer’s patch following exposure to p27 antigen in lumen.
in upper right corner with higher magnification.
Fig. 5. Flow cytometric analysis of the maturation of bone-marrow-derived DCs pulsed with C. perfringens with and without expressing p27. Representative dot
plots of the CD11c+/CD40+ (A) or CD11c+/CD86+ (B) cells. The mean fluorescence intensities (MFI) of CD40 and CD86 after different treatments are shown
in panels C and D, respectively. Error bars are SEs for three independent experiments. The statistical significance of the difference between control group and
treated groups was calculated by Student’s t test. *, P b 0.05. C.P. p27: C. perfringens expressing SIV p27; C.P. Control: C. perfringens containing empty vector.
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p27/108 bacterial cells) is one of the highest antigen
expression levels for bacterial vaccine vectors reported
(DiPetrillo et al., 2000; Gamage et al., 2003). Upon oral
feeding, the recombinant C. perfringens vaccine construct
delivered a large amount of intact p27 fusion protein to the
terminal ileum, indicating p27 protein present in the
inclusion body is protected from the harsh environment of
GI tract. Oral delivery of inclusion bodies carrying viral
antigens have been shown to induce both systemic and
mucosal immune responses without any adjuvant (Kesik et
al., 2004). Therefore, the presence of SIV p27 antigen in the
inclusion body of the recombinant C. perfringens should
induce strong anti-SIV mucosal immune response. Further-
more, DCs in the PPs of the intestine and DCs derived from
bone marrow were capable of taking up and processing the
p27 fusion protein made by sporulating C. perfringens cells.
Such uptake of antigens also resulted in DC maturation.
Collectively, these observations suggest that such delivery
of p27 fusion protein to the terminal ileum should induce
strong mucosal T and B cell responses.
We recognize that, unlike other bacterial and viral-based
vectors, C. perfringens does not invade GI cells and
therefore may appear not to present its antigens through
the classical MHC class I pathway. However, emergingevidence indicates that DCs have a specialized capacity,
known as cross-presentation, for processing exogenous
antigens into the MHC class I pathway (Botarelli et al.,
1991; Zhao et al., 2002). Because DCs in PPs have been
shown to take up p27 fusion protein expressed by the
recombinant C. perfringens vaccine construct, we expect
that the proposed vaccine regimen will induce both cellular
and mucosal immune responses.
The strength of the C. perfringens system for vaccine
development lies with the unique characteristics of the cpe
gene and biology of the organism. These include: (1) cpe
gene promoter is exceptionally strong, expressing high
levels of the CPE protein (which often represents 15% of
total protein in a sporulating cell) (Michael et al., 2001;
Zhao and Melville, 1998); (2) the cpe promoter is highly
regulated, becoming activated only during sporulation
(Michael et al., 2001); and (3) under natural conditions, C.
perfringens quickly multiplies in the small intestine (C.
perfringens has one of the shortest bacterial doubling times,
approximately 10 min) and then sporulates in the small
intestines. After sporulation (starting after approximately 12
h), the mother cell lyses to deliver antigen directly to the PPs
rich terminal ileum that carries antigen-presenting cells, like
DCs; (4) in the C. perfringens system, the antigen is
shielded in inclusion bodies inside bacteria (no proteolysis
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released at the intended immunization site (the terminal
ileum), thereby allowing delivery of large amounts of intact
antigens to the ileum; (5) the problem of preexisting
immunity that may compromise the efficiency of subse-
quent immunization should not be a major problem for C.
perfringens-based vaccine, because it is part of the normal
intestinal microflora.
It has been shown that inactivating the cpe gene renders
C. perfringens avirulent in the intestine of an animal model
(Sarker et al., 1999). Moreover, there is no evidence to date
that genes encoding any toxins of enteric clostridia (e.g., C.
perfringens or C. difficile) are transferable by phages. Nor
has gene exchange between C. difficile and C. perfringens
been documented. There are no reports of C. perfringens
isolates expressing C. difficile toxins A, B, or C. Therefore,
the proposed C. perfringens-based vaccine with cpe gene
deleted should be safe for usage in human. This bproof of
conceptQ study indicates that the C. perfringens-based
vaccine strategy holds great promise for developing a
practical vaccine against SIV/HIV and other pathogens
infecting mucosal surfaces.Materials and methods
Plasmid construction
Standard recombinant DNA techniques and reagents
were used in DNA manipulations involved in the construc-
tion of plasmid cp27. The entire SIV p27 ORF was ampQ
lified by PCR from a molecular cloned SIV17e-Fr with
primers (p27 forward 5V TTCGAACCAGTACAACAAA-
TAGGTG G and p27 reverse 5V CCTAAGGACATTAAQ
TCTA GCCTTCTG) designed to contain BstB1 or Bsu36I
restriction site at the 5Vend of each primer (underlined). The
resultant p27 PCR product (703 bp) was then digested
with these two enzymes. The plasmid pJRC200 (Czeczulin
et al., 1996) was digested with BstB1 and Bsu36I at the
unique restriction sites in the cpe ORF to remove most of the
cpe ORF, including sequences encoding the entire CPE
cytotoxicity region. The digested PCR product and pJRC200
were then ligated with T4 ligase to create a new plasmid,
cp27. The estimated CPE–p27 fusion protein is 32 kDa.
Bacteria and growth condition
Escherichia coli (E. coli) DH5a (Invitrogen) was grown
overnight with shaking at 37 8C in LB medium. Avegetative
culture of C. perfringens (cpe-negative, type A C. perfrin-
gens strain ATCC 3624) was grown for 9 h at 37 8C in fluid
thioglycolate broth (FTG) (Difco). A modified Duncan-
Strong medium (MDS) (Kokai-Kun et al., 1994) was used to
obtain sporulating cultures of C. perfringens. MDS cultures
of C. perfringens were grown for 8 h at 37 8C. All media
were supplemented with 10–20 Ag of chloramphenicol permilliliter for growing transformants containing pJRC200-
based plasmid constructs. The percentage of sporulating C.
perfringens cells formed in MDS was determined by
observation with a phase-contrast microscope.
Transformation of E. coli and C. perfringens with cp27
Classical heat-shock-mediated transformation was used to
introduce cp27 or the control pJRC200 into E. coli DH5a. C.
perfringens cells were transformed using electroporation.
Vegetative cultures of ATCC 3624 were grown at 37 8C to
late log phase in TGY broth (3% Trypticase, 2% glucose, 1%
yeast extract, and 0.1% cysteine), washed twice with SMP
buffer (270 mM sucrose, 1 mMMgCl2, and 7 mMNa2HPO4,
pH 7.3), and then resuspended in 1 ml of SMP buffer. Four
hundred microliters of those washed cells and plasmid DNA
(5 Ag) in 0.4-cm cuvette (Bio-Rad) were placed in a Bio-Rad
Gene pulser set for 2.5 kV and 25 AF. After pulsing, 3 ml of
warm (37 8C) TGY broth was added and the mixture was
incubated for 3 h at 37 8C. An aliquot (100–1000 Al) of this
mixture was plated on brain heart infusion agar (Difco) plate
containing 10 Ag/ml of chloramphenicol. Those plates were
incubated for 24 h at 37 8C in an anaerobic atmosphere,
created using a BBL GasPak jar.
Western blot analysis
C. perfringens cells were harvested, washed, and soni-
cated in PBS after growing in FTG or MDS. The cell lysates
were analyzed for the presence of p27 protein by Western
immunoblots. Briefly, proteins in the cell lysate were
separated on 12% of sodium dodecyl sulfate-polyacylamide
gel electrophoresis (SDS-PAGE) and then transferred to a
nitrocellulosemembrane. The membrane was hybridized first
with an SIV-positive monkey serum and then washed and
incubated with horseradish peroxidase-conjugated goat anti-
monkey antibody (Nordic Immunological Laboratories,
Tilburg, Netherlands). The protein bands were detected with
SuperSignal chemiluminescent reagent (Pierce, Rockford,
IL) and visualized by exposing to X-ray film. The amount of
p27 present in the cell lysate was quantitated by densitometric
comparisons against a series of dilutions of recombinant SIV
p55 (a precursor of p27 from NIH AIDS Research and
Reference Reagent Program) as standards.
Immunoelectron microscopy
The pellet of sporulated C. perfringens was fixed with
2% paraformaldehyde and 0.01% glutaraldehyde in 0.1 M
PBS, washed, and cryoprotected in 2.3 M sucrose contain-
ing 20% polyvinylpyrrolidone. The bacteria were then
mounted on aluminum cryopins and frozen in liquid
nitrogen. Ultrathin sections (70–100 nm) were cut with an
ultramicrotome, washed first with PBS, and then with PBS
containing 0.5% BSA and 0.15% glycine (PBG buffer)
followed by a 30-min incubation with 5% normal serum in
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antibody for 1 h and then labeled with colloidal gold linked
secondary antibody at room temperature for 1 h (Amersham,
Piscataway, NJ). Sections were washed, fixed, and stained
in 2% neutral uranyl acetate. After washing again with
ddH2O, the fixed sections were stained again 2 min in 4%
uranyl acetate and embedded in 1.25% methyl cellulose.
Stained sections were observed on a JEOL JEM 1210
electron microscope (Peabody, MA) at 80 kV.
Uptake of C. perfringens expressing SIV p27 antigen by
cultured DCs and DCs in the PPs
Mouse bone-marrow-derived dendritic cells (DCs) were
prepared as described by Bonham et al. (2002) with
modifications. Briefly, bone marrow cells flushed from the
femurs and tibias of mice were seeded and cultured at a
density of 4  106 cells per well of a 24-well plate in RPMI
1640 containing 10% heat-inactivated fetal bovine serum,
1% l-glutamine, 1% sodium pyruvate, 1% nonessential
amino acids, 0.025 M 2-mercaptoethanol and 1% penicillin–
streptomycin, 4 ng/ml GM-CSF, and 4 ng/ml IL-4. At day 2,
nonadherent cells were removed and 50% of the supernatant
was replaced with fresh cytokine-containing medium. On
day 6, the cells in the plate, which were 40–60% CD11c
positive, were co-incubated with 5  106 sporulated C.
perfringens expressing SIV p27 for 2 h. The DCs were then
washed with PBS to remove the noningested bacteria, fixed
with 2% paraformaldehyde, and examined by immunofluor-
escence microscopy with anti-CD11c (PE-conjugated) and
p27 antibodies.
To measure antigen uptake by DCs in PPs, a freshly
isolated 3–5-cm section of a mouse ileum containing one PP
was ligated at both ends. Two hundred microliters (1.5 
109 spores) of lysate prepared from sporulating C. perfrin-
gens cells expressing the fusion protein were injected inside
the lumen of the ligated segment. After incubation for 3.5 h
in culture medium, the PP in this segment was washed,
fixed, and subjected to in situ immunofluoresence staining
with anti-CD11C and anti-p27 antibodies for detection of
DCs and p27, respectively.
Maturation of DCs by C. perfringens expressing SIV p27
To examine DC maturation by C. perfringens, 1  106 to
2  106 bone-marrow-derived DCs from day 5 or 6 of
culture were cocultured for 2 h with 8  105 of either
sporulated C. perfringens expressing p27 or sporulated
vector control C. perfringens, p27 protein (final concen-
tration 250 ng/ml) (Advanced BioScience Laboratories,
Inc., Kensington, MD), or LPS (0.5 Ag/ml). Bacteria, p27
protein, and LPS were then removed by centrifugation.
After 24 h of culture, cells were harvested and stained with
FITC-conjugated antibodies against CD40 or CD86 and PE-
conjugated antibody against CD11c (BD Biosciences
Pharmingen, San Diego, CA). Flow cytometry wasperformed on a Becton-Dickinson FACSort flow cytometer,
and data were collected on 5000 cells. Analysis of data was
performed using WinMDI (version 2.8)and Cytomation
Summit packages (version 3.1 build 844).
Animals, oral feeding, and detection of SIV p27 expressed in
C. perfringens
BALB/c female mice were purchased from the Charles
River Laboratories, Inc. (Wilmington, MA), housed in a
pathogen-free facility, and fed rodent chow and water ad
libitum. The mice were used between 6 and 10 weeks of
age. Mice were orally fed with the sporulating C.
perfringens recombinants. Ninety minutes after administra-
tion, the entire small intestine was divided into six equal
segments and the contents of each segment were extracted
vigorously with PBS containing protease inhibitors and then
pelleted down by centrifugation. The pellet from each
segment was subjected to a Western blot analysis.
Statistical analysis
The statistical significance of the difference between
control group and treated groups was calculated by
Student’s t test.Acknowledgments
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